Download PDF

1. Company Snapshot

1.a. Company Description


Founded in 1994, Alexandria pioneered this niche and has since established a significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle.Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, technology, and agtech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success.Alexandria also provides strategic capital to transformative life science, technology, and agtech companies through our venture capital platform.


We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.">

Alexandria Real Estate Equities, Inc.(NYSE:ARE), an S&P 500® urban office real estate investment trust ("REIT"), is the first, longest-tenured, and pioneering owner, operator, and developer uniquely focused on collaborative life science, technology, and agtech campuses in AAA innovation cluster locations, with a total market capitalization of $31.9 billion as of December 31, 2020, and an asset base in North America of 49.7 million square feet ("SF").The asset base in North America includes 31.9 million RSF of operating properties and 3.3 million RSF of Class A properties undergoing construction, 7.1 million RSF of near-term and intermediate-term development and redevelopment projects, and 7.4 million SF of future development projects.


Founded in 1994, Alexandria pioneered this niche and has since established a significant market presence in key locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle.Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, technology, and agtech campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success.Alexandria also provides strategic capital to transformative life science, technology, and agtech companies through our venture capital platform.


We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Show Full description

1.b. Last Insights on ARE

Alexandria Real Estate Equities, Inc.'s recent performance has been driven by several positive factors. The company reported strong leasing activity, with 1.2 million square feet leased in Q4 2025, up 14% year-over-year. Additionally, several institutional investors have increased their stakes in the company, including B&I Capital AG, which grew its stake by 49.2%. Eagle Strategies LLC and Kawa Capital also initiated new positions in the company. Furthermore, the company's management team hosted an Analyst/Investor Day, providing insights into its growth strategy. Despite some challenges, ARE's strong balance sheet and high tenant retention rate position it for long-term recovery.

1.c. Company Highlights

2. Alexandria Real Estate Equities' 2025 Earnings: Navigating a Challenging Landscape

Alexandria Real Estate Equities reported FFO per share diluted as adjusted of $2.16 for 4Q '25, beating estimates of $2.15, and $9.01 for the year, meeting the midpoint of prior guidance. The company's leasing volume was up 14% over the prior 4-quarter average, with 393,000 rentable square feet of vacant space leased, almost double the quarterly average over the last 5 quarters. Occupancy was 90.9% at the end of 2025, up 30 basis points from the prior quarter.

Publication Date: Feb -09

📋 Highlights
  • FFO Guidance Met: Achieved $2.16 FFO/share in Q4 2025 ($9.01 annualized), aligning with midpoint of prior guidance.
  • High Occupancy Growth: Ended 2025 with 90.9% occupancy, up 30 bps QoQ, despite forecasting a Q1 2026 dip.
  • Aggressive Dispositions: Completed $1.5B in asset sales across 26 transactions, with $180M under contract for 2026.
  • Balance Sheet Strength: Maintained $5.3B liquidity, 5.7x net debt/EBITDA leverage, and long-term debt maturity profile.
  • Leasing Momentum: 1.2M sq ft leased in Q4 (14% above prior 4-quarter average), driven by private biotech demand.

Operational Highlights

The company achieved significant operational execution in 2025, including $1.5 billion of dispositions across 26 transactions. Same-property net operating income was down 6% and 1.7% on a cash basis for the fourth quarter. The company's disposition plan includes $2.9 billion in asset sales, with a significant portion being land that will be sold to residential developers.

Leasing and Occupancy Outlook

The company expects occupancy to dip in the first quarter of 2026 but grow in the second half of the year. Joel Marcus noted that the fourth quarter saw a notable lack of leasing for public biotech, which is a critical mainstay of the industry. The company is cautiously optimistic about the leasing pipeline, with a focus on meeting the market and keeping rental rates stable.

Valuation and Growth Prospects

With a P/E Ratio of -6.66 and an EV/EBITDA of 60.76, the market is pricing in significant challenges for the company. Analysts estimate next year's revenue growth at -1.6%. The company's strong balance sheet, with $5.3 billion in liquidity, and modest leverage of 5.7x for net debt to adjusted EBITDA, provides a foundation for navigating the challenging landscape.

Capital Allocation and Development Exposure

The company prioritizes paying down debt before considering buybacks and aims to be net neutral on non-real estate investments. Development exposure as a percentage of total assets is expected to decrease from 20% to 15% this year, with a focus on core assets and potential joint ventures for capital recycling.

Industry Sentiment and Future Prospects

The company believes the industry has a promising future, with only 10% of diseases addressed and 90% remaining. The FDA is working to compress the time from discovery to commercialization. The recovery timeline for life science is estimated to be 2-3 years for core markets and 4-5 years for submarkets.

3. NewsRoom

Card image cap

The Hormuz Halt

Mar -08

Source: seekingalpha.com

Card image cap

2 Retirement Yield Picks That Give You The Right To Win

Mar -05

Source: seekingalpha.com

Card image cap

Alexandria Stock Rises 19.2% in 3 Months: Will the Trend Continue?

Mar -05

Source: zacks.com

Card image cap

Seven S&P500 Ideal 'Safer' March Dividend Dogs

Mar -04

Source: seekingalpha.com

Card image cap

Cash COWs: 12 High-Yield REITs With Safe Dividends

Mar -02

Source: seekingalpha.com

Card image cap

Alexandria Real Estate Equities, Inc. Declares Cash Dividend of $0.72 per Common Share for 1Q26

Mar -02

Source: prnewswire.com

Card image cap

Socorro Dumps Its Entire Alexandria Real Estate (ARE) Position Worth $5.2 Million

Mar -01

Source: fool.com

Card image cap

Seeking Shelter In A Shifting Market

Mar -01

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.77%)

6. Segments

Rental - Same Properties

Expected Growth: 5.8%

Alexandria Real Estate Equities' 5.8% Rental - Same Properties growth is driven by strong life science and technology industry trends, increasing demand for lab and office space, and strategic property acquisitions and developments in high-growth markets, such as Boston and San Francisco.

Rental - Non-Same Properties

Expected Growth: 5.9%

Alexandria Real Estate Equities' 5.9% growth in Rental - Non-Same Properties is driven by increasing demand for life science and technology facilities, strategic acquisitions, and rent escalations. Additionally, the company's focus on high-growth markets, such as Boston and San Francisco, and its ability to maintain high occupancy rates also contribute to its growth.

Tenant Recoveries - Same Properties

Expected Growth: 5.5%

The 5.5% growth in Tenant Recoveries - Same Properties is driven by increasing rental rates, high occupancy levels, and a strong life science industry demand. Additionally, Alexandria's strategic property acquisitions and redevelopment initiatives have enhanced the quality of its portfolio, leading to higher recoveries from tenants.

Tenant Recoveries - Non-Same Properties

Expected Growth: 5.7%

Alexandria Real Estate Equities' 5.7% growth in Tenant Recoveries - Non-Same Properties is driven by increasing demand for life science and technology spaces, strategic lease renewals and expansions, and rising reimbursement rates for biotech and pharmaceutical companies. Additionally, the company's focus on high-quality, amenity-rich properties and strong relationships with tenants contribute to this growth.

Other - Non-Same Properties

Expected Growth: 6.1%

Alexandria Real Estate Equities' 6.1% growth in Other - Non-Same Properties is driven by strategic acquisitions, increasing demand for life science and technology facilities, and expansion into high-growth markets. Additionally, the company's focus on providing mission-critical infrastructure and its strong relationships with top-tier tenants contribute to its growth momentum.

Other - Same Properties

Expected Growth: 5.6%

Alexandria Real Estate Equities' 5.6% growth in 'Other - Same Properties' is driven by increasing demand for life science and technology facilities, strategic acquisitions, and rent escalations. Additionally, the company's focus on high-quality, Class A properties in prime locations, such as San Francisco and Boston, contributes to its growth.

7. Detailed Products

Life Science Real Estate

Alexandria Real Estate Equities, Inc. provides life science real estate solutions, including laboratory and office space, to life science companies, enabling them to focus on their core business of discovering and developing new treatments and therapies.

Technology and Office Space

The company offers technology and office space solutions to technology and office tenants, providing flexible and amenity-rich environments that foster innovation and collaboration.

AgTech Real Estate

Alexandria provides AgTech real estate solutions, including greenhouses, research facilities, and office space, to companies focused on agricultural technology and sustainable agriculture.

Manufacturing and Logistics Space

The company offers manufacturing and logistics space solutions to life science and technology companies, providing flexible and efficient facilities to support their operations.

8. Alexandria Real Estate Equities, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Alexandria Real Estate Equities, Inc. is medium due to the availability of alternative investment options in the real estate industry.

Bargaining Power Of Customers

The bargaining power of customers for Alexandria Real Estate Equities, Inc. is low due to the company's strong brand reputation and diversified portfolio of properties.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Alexandria Real Estate Equities, Inc. is medium due to the company's dependence on a few large suppliers for construction materials and services.

Threat Of New Entrants

The threat of new entrants for Alexandria Real Estate Equities, Inc. is high due to the relatively low barriers to entry in the real estate industry and the increasing popularity of real estate investment trusts (REITs).

Intensity Of Rivalry

The intensity of rivalry for Alexandria Real Estate Equities, Inc. is high due to the competitive nature of the real estate industry and the presence of several large and established players.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 38.78%
Debt Cost 3.95%
Equity Weight 61.22%
Equity Cost 9.36%
WACC 7.26%
Leverage 63.33%

11. Quality Control: Alexandria Real Estate Equities, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Boston Properties

A-Score: 5.4/10

Value: 5.7

Growth: 3.2

Quality: 4.1

Yield: 8.0

Momentum: 4.0

Volatility: 7.3

1-Year Total Return ->

View Full Report
Stock-Card
Cousins Properties

A-Score: 5.3/10

Value: 4.9

Growth: 2.7

Quality: 4.2

Yield: 8.0

Momentum: 3.5

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Alexandria Real Estate Equities

A-Score: 5.3/10

Value: 7.3

Growth: 4.6

Quality: 4.7

Yield: 9.0

Momentum: 0.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Vornado Realty

A-Score: 5.2/10

Value: 7.4

Growth: 2.2

Quality: 6.6

Yield: 6.0

Momentum: 3.5

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
Douglas Emmett

A-Score: 4.9/10

Value: 4.7

Growth: 4.6

Quality: 3.3

Yield: 9.0

Momentum: 1.5

Volatility: 6.3

1-Year Total Return ->

View Full Report
Stock-Card
SL Green Realty

A-Score: 3.9/10

Value: 2.5

Growth: 0.9

Quality: 3.8

Yield: 9.0

Momentum: 2.0

Volatility: 5.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

51.18$

Current Price

51.18$

Potential

-0.00%

Expected Cash-Flows